Sobi™ Keeps the Partner Products Business Area as an Integral Part of the Company

STOCKHOLM, June 5, 2017 /PRNewswire/ --

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that the Partner Products business area will remain an integral part of Sobi's business model for the purpose of creating value when taking the company to the next level. Thereby, discussions regarding a potential sale of the Partner Products business area, which Sobi confirmed were ongoing in a press release on 3 February 2017, have been terminated. Sobi will continue to build on the results of the growing haemophilia business and create value through its other rare disease portfolios in the years to come.

"Our Partner Products portfolio is a valuable rare disease platform in Sobi's business today. We have assessed the options to potentially divest the portfolio, and the conclusion is that going forward this interesting business element will continue to serve as an integral part of Sobi, giving us access to new earnings streams, and supporting both our commercial footprint and attractiveness as a business partner in Europe, the Middle East, North Africa and North America," says Guido Oelkers, CEO and President of Sobi.

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Charlotte af Klercker, Senior Communications Manager, at 15:45 CET on 5 June 2017.

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

SOURCE Swedish Orphan Biovitrum AB